Research ArticleArticle
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio and Shephard Mpofu
The Journal of Rheumatology January 2014, jrheum.130637; DOI: https://doi.org/10.3899/jrheum.130637
Mark C. Genovese
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Patrick Durez
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Hanno B. Richards
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Jerzy Supronik
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Eva Dokoupilova
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Jacob A. Aelion
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Sang-Heon Lee
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Christine E. Codding
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Herbert Kellner
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Takashi Ikawa
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Sophie Hugot
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Gregory Ligozio
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Shephard Mpofu
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
Article Information
jrheum.130637
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online January 15, 2014.
Article Versions
- You are currently viewing a Latest version of this article (January 15, 2014 - 12:30).
- View the most recent version of this article
Copyright & Usage
© 2014 The Journal of Rheumatology
Author Information
- Mark C. Genovese,
- Patrick Durez,
- Hanno B. Richards,
- Jerzy Supronik,
- Eva Dokoupilova,
- Jacob A. Aelion,
- Sang-Heon Lee,
- Christine E. Codding,
- Herbert Kellner,
- Takashi Ikawa,
- Sophie Hugot,
- Gregory Ligozio and
- Shephard Mpofu
- From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland.
M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG.
Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu
Accepted for publication November 8, 2013.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu
The Journal of Rheumatology Jan 2014, jrheum.130637; DOI: 10.3899/jrheum.130637
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu
The Journal of Rheumatology Jan 2014, jrheum.130637; DOI: 10.3899/jrheum.130637